Carrying the VEGFA-c.232-28C>T SNP has been associated with increased response to bevacizumab or ranibizumab in people with macular degeneration, as compared to genotype CC after 3, 6, and 12 months of treatment [24], and VEGFA- rs833069 CC+CT genotypes have been demonstrated to have greater decreases in central subfield macular thickness (CSMT) between baseline and 3 (p = 0.002) or 6 (p = 0.001) months of treatment, as compared to those with the TT genotype [25]. Here, VEGFA is linked to macular degeneration.